Theralase Technologies Inc. founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound healing. When combined with its patented, light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria, viruses as well as microbial pathogens associated with food contamination.

1. Theralase Quarterly Newsletter - December 2011
An update for clients, investors and employees
Theralase’s Patented Photo Dynamic Compound (PDC) Effective in Destruction
of Cancerous Tumours in Live Animals
Theralase announced on December 1st that its patented light activated PDC technology was successful in
destroying cancerous tumours located under the skin of a live animal. We are excited that our PDC
technology has achieved this critical milestone because we have now validated our technology in the
destruction of cancerous tumours in live animals. The Theralase PDC treatment was successful and well
tolerated by the animals and as a result, this preclinical success will help the Company to identify the
leading PDC to take forward for additional animal and human cancer destruction applications. Now that
our PDC technology has been proven successful in the destruction of cancerous tumours in animals, this
may lead to a new significant revenue stream for the Company in the destruction of cancerous tumours
in companion animals and humans in the not too distant future.
Theralase Light Activated Photo Dynamic Compounds Successfully Destroy E.
coli Bacteria
Theralase has developed a new application for its patented Photo Dynamic Compounds (PDCs);
specifically, the destruction of Escherichia coli, commonly known as E. coli, a widely prevalent disease
causing bacteria. Theralase announced on September 14th, that our research demonstrated that our
Photo Dynamic Therapy (PDT) destruction of E. coli bacteria is effective and represents a significant
opportunity in the area of disinfection and sterilization of bacterial pathogens that may cause serious
and potentially life-threatening illness. Commercialization of these technologies becomes more and
more apparent, as our research and development progresses, allowing us the opportunity to introduce
these technologies to the world in a variety of diverse applications. The next steps for Theralase will be
1

2. to prove out the technology further in a lab setting and then develop a pilot project with a major food
manufacturer.
Theralase and George Brown College Join in Government-Funded Research to
Combat Food Contamination
In the wake of many outbreaks of consumer food contaminations associated with microbial pathogens
such as Listeria monocytogenes (Listeria) and Escherichia coli (E. coli) and their various strains, Theralase
completed a the study with George Brown College to determine the feasibility of using our patented
PDCs for sanitation in the food service, food manufacturing and medical industries. Given their history
and pedigree in culinary arts and additional focus on food applied research, the George Brown College
Centre for Hospitality and Culinary Arts was a perfect partner for applied research in new and innovative
sanitation protocols and techniques using the company’s patented lasers and photo dynamic
compounds. The results proved that the Theralase PDC technology is highly effective in the destruction
of food related pathogens.
Theralase Introduces Low Priced Laser Series - New TLC-900 Laser Series Offers
Theralase’s Renowned Clinical Performance at Lower Prices
On November 17th Theralase launched a new version of the high performance Theralase TLC-1000
therapeutic medical laser series, known as the Theralase TLC-900 series, which effectively eliminates the
controller and allows the practitioner to operate the laser probes independently. This TLC-900 system
allows the practitioner the ability to benefit from the high performance Theralase laser system
technology, albeit with less features and versatility than the TLC-1000 series, but at an overall cost
savings. We believe that this will open up the therapeutic laser market and give practitioners the ability
to choose a high performing product, such as the Theralase, at the same price points as lower end, non-
effective, competitive technology.
Theralase Closes Equity Financing
On October 25th Theralase Technologies Inc. announced that it closed a non-brokered private placement
of 1,050,000 units at a price of Cdn $0.40 per Unit for gross proceeds of Cdn $420,000.00. Each Unit
consists of one common share in the capital of the Company and one-half of one non-transferable
common share purchase warrant. Each whole Warrant entitles the purchaser to purchase one additional
common share in the capital of the Company until October 25, 2013 at a price of Cdn $0.60 per Warrant
Share. The securities issued under the Private Placement including any shares issued upon exercise of
the Warrants are subject to a four month hold period, expiring February 25, 2012.
The company intends to utilize the proceeds of the offering to provide additional working capital to
further develop the Company's prospects in a number of areas; specifically:
• Support of small animal cancer trials at the Ontario Cancer Institute, Princess Margaret Hospital,
University Health Network.
2

3. • Research and development of Photo Dynamic Compounds used in conjunction with the patented
Theralase laser technology in the destruction of bacteria in the area of food safety.
• TLC-1000 and TLC-900 series therapeutic medical laser marketing and sales expansion into the US.
• TLC-2000 therapeutic medical biofeedback laser commercialization.
Theralase Publishes White Paper
On October 27th Theralase released a pivotal White Paper written by Chief Scientific Officer,
Arkady Mandel, MD, Ph.D., D.Sc. entitled
“UNDERSTANDING THE MECHANISMS OF LOW LEVEL LASER THERAPY (LLLT)”
Low Level Laser Therapy (LLLT) is a rapidly growing modality used in the rehabilitation and physical
therapy markets. A number of safe and beneficial therapeutic effects of LLLT have been reported in
numerous clinical conditions; however, despite many reports of positive findings from experiments
conducted in-vitro, in-vivo animal models and in randomized controlled clinical trials worldwide, the use
of this scientifically proven, clinically effective, non-invasive and anti-inflammatory human modality has
yet to find mainstream adoption by medical doctors.
The aim of the White Paper is to:
1) introduce the unfamiliar reader, with some medical background, to the contemporary concept of LLLT
and its pathophysiological significance,
2) review the role of the mitochondrial pathway in the mechanisms of LLLT,
3) provide necessary practical guidance based on scientific and clinical experience,
4) assist manufacturers in their research and development,
5) help health care practitioners choose and use an adequate light therapy device,
6) outline the prospects of LLLT as an avenue to treat chronic inflammation and pain and to aid in an
effective clinical practice.
The White Paper may be accessed from www.theralase.com.
OUTLOOK
Theralase will continue to focus on increasing product sales of the TLC-1000 laser technology and the
newly released TLC-900 controllerless laser series in the Canadian, US and international markets in 2012,
supported by new independent scientific research confirming the effectiveness of Theralase’s
proprietary and patented technology. Theralase will commercialize its patented TLC-2000 Biofeedback
technology for launch in the third quarter of 2012, while researching and developing its patented TLC-
3000 Photo Dynamic Compounds targeting the destruction of cancer, bacteria and viruses.
The groundwork has been laid for significant growth. Our proven patented technology has no equal and
our ability to dramatically scale sales and marketing geographically as well as demographically will allow
Theralase a significant first mover market advantage. Theralase is currently debt free as it utilizes its
profits from the sale of its TLC-1000 Therapeutic Medical Laser platform to pay for its future growth in
the form of the launch of the TLC-900 series, the launch of the TLC-2000 Biofeedback Therapeutic Laser
3

4. Technology and the commercialization of the TLC-3000 Photo Dynamic Compound Cancer Destruction
Technology.
For more information please contact:
Roger Dumoulin-White
President & CEO,
416-447-8455 ext. 225
rwhite@theralase.com
Greg Bewsh
Director of Investor Relations,
416-447-8455 ext. 262
gbewsh@theralase.com
4